Cytarabine ocfosfate

Drug Profile

Cytarabine ocfosfate

Alternative Names: ara CMP stearyl ester; C 18 PCA; Cytarabine phosphate stearate; Estarabine; Phosteabine sodium; Starasid; YNK 01

Latest Information Update: 09 May 2007

Price : $50

At a glance

  • Originator Nippon Kayaku; Yamasa Corporation
  • Class Antineoplastics; Arabinonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Leukaemia
  • Discontinued Cancer

Most Recent Events

  • 06 Mar 2003 A study has been added to the Cancer therapeutic trials section
  • 29 Nov 2000 A phase II study has been added to the Cancer therapeutic trials and adverse events sections
  • 06 May 1997 Launched for Leukaemia in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top